Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingPresbyterian Plasma Genomic Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentPresbyterian Health PlanPolicy 39.0

    Genetic Testing, Plasma-Based Genomic Profiling in Solid Tumors

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy 39.0 alerts

    Get alerted when Policy 39.0 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for plasma-based, cell-free DNA/RNA genomic profiling tests used in solid tumors for Commercial, Medicaid, and Medicare members, subject to Wisconsin LCD L38168, related LCA A57936, and the member’s specific benefit plan.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyGenetic Testing, Plasma-Based Genomic Profiling in Solid Tumors
    Policy CodePolicy 39.0
    Change TypeMaterial coverage revision
    Effective DateN/A
    Last ReviewMar 25, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for listed plasma-based genomic profiling services through Pres Online.
    SourceLink
    POLICY UPDATE CHANGES

    Code 0487U was changed from investigational and experimental to a covered service and requires prior authorization.

    Code 0571U was added as a covered service and requires prior authorization.

    Code 0485U was added to the prior authorization configuration because it is listed in the covered Group 1 section of the LCA.

    The policy continues to retain code 0409U even though CMS deleted it from LCA Group 1, with prior authorization required.

    Required

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Utilization management requirement
    3Applicable product lines
    L38168 / A57936Governing coverage criteria
    0179UExplicitly non-covered code
    10Codes requiring prior authorization

    Coverage Criteria

    Coverage under Wisconsin MolDX LCD/LCA

    Covered services are determined using the following external coverage criteria:

    External LCD/LCA criteria

    • The requested service must satisfy the applicable coverage requirements in Wisconsin LCD L38168, MolDX: Plasma-Based Genomic Profiling in Solid Tumors, and related LCA A57936.

      The detailed diagnosis and medical-necessity criteria are not reproduced in this policy; consult the referenced LCD and LCA.

    Code 0179U (Resolution ctDx Lung) is non-covered for all product lines under LCA A57936, Group 2.

    Covered and Configured Codes

    CPT/HCPCS CodesmixedCovered
    81445Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis
    81479Unlisted molecular pathology procedure
    81462Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants and rearrangements
    81463Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis, copy number variants, and microsatellite instability
    81464Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements
    0485UOncology (solid tumor), cell-free DNA and RNA by next-generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived single-nucleotide variants, small insertions/deletions, copy number alterations, fusions, microsatellite instability, and tumor mutational burden; includes Caris Assure
    0571UOncology (solid tumor), DNA (80 genes) and RNA (10 genes), by next-generation sequencing, plasma, including single-nucleotide variants, insertions/deletions, copy-number alterations, microsatellite instability, and fusions, reported as clinically actionable variants; includes LiquidHALLMARK
    0179USequence analysis of 23 genes, including single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, and copy number variations, with report of significant mutation(s); Resolution ctDx Lung
    Not CoveredHCPCSNot Covered
    0179UResolution ctDx Lung; non-covered under LCA A57936 Group 2
    Publication-history and configuration codesHCPCS
    0487UNorthstar Select; covered under LCA A57936 Group 1 after successful technical assessment
    0409ULiquidHALLMARK; retained in this policy and requires prior authorization even though CMS deleted the code from Group 1
    0326UGuardant360; prior authorization required
    0428UDeleted code; removed from the policy in the 2025 annual review

    Provider Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for applicable plasma-based genomic profiling services. Submit requests through Pres Online.

    • Affected codes: 81445, 81462, 81463, 81464, 81479, and 0326U.
    • Pres Online: https://ds.phs.org/preslogin/index.jsp
    Documentation Required

    Coverage-Supporting Documentation

    Providers must maintain or have access to appropriate documentation when requested to support coverage under the applicable LCD, LCA, or other referenced guideline criteria.

    • See Wisconsin LCD L38168 and related LCA A57936 for applicable coverage requirements.

    Policy Background

    This policy addresses genomic profiling of solid tumors using plasma or other cell-free nucleic acid, including DNA and RNA sequencing. Testing may evaluate sequence variants, copy-number changes, rearrangements or fusions, microsatellite instability, tumor mutational burden, and other clinically actionable findings. Coverage determinations follow Wisconsin LCD L38168 and related LCA A57936; the detailed diagnosis and medical-necessity criteria are not reproduced in this policy.

    Plasma-Based Genomic Profiling

    Plasma-based genomic profiling
    Specimen typePlasma or other cell-free nucleic acid, including cell-free circulating DNA
    Sequencing performedDNA analysis or combined DNA and RNA analysis using genomic sequence analysis panels or next-generation sequencing
    Genomic findings evaluatedSequence variants, copy-number alterations or variants, and gene rearrangements or fusions
    Additional biomarkersMicrosatellite instability and tumor mutational burden may also be assessed
    Clinical applicationGenomic profiling of solid tumors, including reporting of clinically actionable variants

    Covered Services and Indications

    Plasma-Based Genomic Profiling in Solid Tumors

    Covered when ALL of the following are met:

    ALL of the following

    • The requested test is plasma-based genomic profiling for a solid tumor using cell-free circulating DNA or other cell-free nucleic acid, with DNA or combined DNA and RNA analysis as applicable.
    • The service is billed using a CPT, HCPCS, or PLA code and laboratory/test configuration recognized as covered under the applicable MolDX LCD/LCA; code 0179U (Resolution ctDx Lung) is not covered under LCA A57936 Group 2.
    • The requested service satisfies the applicable coverage and diagnosis requirements in Wisconsin LCD L38168 and related LCA A57936.

      This policy does not reproduce the specific tumor-type, diagnosis, or medical-necessity criteria. Consult the referenced LCD and LCA for the applicable criteria.

    Not Covered Services

    Resolution ctDx Lung under code 0179U is non-covered for all product lines under LCA A57936, Group 2.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyGenetic Testing, Plasma-Based Genomic Profiling in Solid Tumors
    Policy CodePolicy 39.0
    Change TypeMaterial coverage revision
    Effective DateN/A
    Last ReviewMar 25, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for listed plasma-based genomic profiling services through Pres Online.
    SourceLink
    On This Page
    Coverage CriteriaCovered and Configured CodesProvider RequirementsPolicy BackgroundPlasma-Based Genomic ProfilingCovered Services and IndicationsNot Covered Services
    Note

    Verify Member Benefits

    Verify the member’s specific benefit plan and Schedule of Benefits before submitting a request, because Presbyterian Health Plan products may have different coverage provisions.

    Denial Risk

    Benefit-Plan Limitations

    Coverage may be unavailable or more limited when the member’s benefit plan or Schedule of Benefits excludes the service or provides narrower benefits than this policy.

    Denial Risk

    LCD/LCA Criteria Not Met

    Requests must satisfy the applicable Wisconsin LCD and LCA criteria. If the criteria are not met or supporting documentation is insufficient, coverage may be denied.

    • Apply Wisconsin LCD L38168, MolDX: Plasma-Based Genomic Profiling in Solid Tumors, and related LCA A57936.
    • Submit documentation demonstrating that the applicable diagnosis and coverage criteria are met.
    Billing Rule

    Non-Covered Code: 0179U

    Code 0179U, Resolution ctDx Lung, is configured as non-covered for all product lines of business.

    • Non-covered per LCA A57936, group 2.